Eidos Therapeutics, Inc.
Q3 2021 13F Holders
Symbol
EIDX
CUSIP
98422L107
Type
Equity
Class
COM
Num filings
78
Total reported value, excl. options
$41.2 M
Compare 2021 Q3 to
2022 Q2
2022 Q1
2021 Q4
2021 Q2
2021 Q1
2020 Q4
2020 Q3
2020 Q2
2020 Q1
2019 Q4
2019 Q3
2019 Q2
2019 Q1
2018 Q4
2018 Q3
2018 Q2
Manager
Report Date
Value ($000)
Shares
Option Type